RAT-HEMATO : Return to Work After Malignant Hemopathy
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Return to work (RTW) of patients after cancer treatment has been a topic of growing interest for the past two decades. Advances in cancer care have led to better patient survival, with some cancers considered as chronic or even cured diseases. The return of patients to their "pre-cancer life" can thus become an objective. Indeed, RTW after cancer is associated with improved quality of life for patients in several studies (improved financial status, improved social contacts, return of functional abilities and improved self-esteem). However, many difficulties can interfere with RTW. Many factors have been identified: disease, treatment, patient and occupational factors. The feeling of "return-to-work self-efficacy" is one of the main psychological determinants and its interest has been recently demonstrated in oncology. It corresponds to a cognitive mechanism based on expectations and/or beliefs of an individual about being able to carry out the actions required to achieve a goal, in this case RTW. The majority of studies on RTW concerns solid cancer and are retrospective. Very few studies have focused on hematological malignancies, whose prognosis was, until recently, worse. Moreover, very few interventional studies exist. There is therefore a significant need for prospective studies with appropriate methodological tools to reliably assess the benefit of interventional measures on RTW. The investigators propose to conduct a prospective, comparative, randomized, multicenter study evaluating the impact of an early RTW-consultation in patients who have been treated for a hematological malignancy. The investigators hypothesize that this consultation will improve patients' RTW rates and RTW quality.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Choroba krwi (białaczka, chłoniak, szpiczak) opanowana po zakończeniu leczenia
- •Chemioterapia indukcyjna/konsolidacyjna ukończona
- •Wiek 18-55 lat
- •Pracował(-a) co najmniej 6 miesięcy w ciągu 2 lat przed diagnozą
- •Jeszcze nie wrócił(-a) do pracy od czasu diagnozy
- •Podpisana świadoma zgoda na udział w badaniu
✗ Disqualifies
- •Pacjent wyraźnie nie chce wracać do pracy
- •Brak ubezpieczenia społecznego
- •Pacjent pod opieką prawną lub kuratelem
- •Nie mówi po francusku
- •Poważne problemy z myśleniem uniemożliwiające uczestnictwo w badaniu
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 55 Years
- Last updated (source)
- August 10, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (9)
Angers University hospital
Angers, France
Brest University Hospital, Morvan Site
Brest, France
Caen University hospital
Caen, France
Le Havre Hospital Group
Montivilliers, France
Pays de Morlaix Hospital
Morlaix, France
Rennes University Hospital, Pontchaillou site
Rennes, France
Centre Henri Becquerel
Rouen, France
Rouen University Hospital
Rouen, France
Tours University Hospital, Bretonneau Site
Tours, France
Trial contact
Jérome PAILLASSA, MD
Aline SCHMIDT, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/11/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.